Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial

医学 安慰剂 内科学 随机对照试验 杜皮鲁玛 胃肠病学 生活质量(医疗保健) 不利影响 意向治疗分析 临床试验 安慰剂对照研究 随机化
作者
Nirmala Prabu Gonsalves,Evan S. Dellon,Kara Kliewer,Tetsuo Shoda,Regina Yearout,Seema Sharma Aceves,Nicoleta C. Arva,John A. Besse,Julie M. Caldwell,Mirna Chehade,Amaziah T. Coleman,Margaret H. Collins,Sara Anvari,Gary W. Falk,Sandeep Kumar Gupta,Girish Hiremath,David A. Katzka,Paneez Khoury,John Leung,Calies D. Menard-Katcher
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier BV]
卷期号:11 (8): 672-688 被引量:9
标识
DOI:10.1016/s2468-1253(26)00116-0
摘要

BACKGROUND: Eosinophilic gastritis currently has no approved treatments and is postulated to be driven by type 2 inflammation. Dupilumab blocks type 2 cytokines IL-4 and IL-13 and has efficacy in multiple diseases characterised by type 2 inflammation, including eosinophilic oesophagitis. We aimed to assess the efficacy and safety of dupilumab in patients with eosinophilic gastritis. METHODS: DEGAS was a proof-of-concept, phase 2, multicentre, randomised controlled trial consisting of a 12-week, double-blind, placebo-controlled period, followed by a 24-week open-label extension period. Patients aged 12-70 years from 11 hospitals in the USA with histologically active eosinophilic gastritis (≥30 eosinophils per high-power field [HPF] in at least five HPFs in the gastric antrum and/or body) and moderate-to-severe symptoms occurring at least 2 days per week in the 2 weeks before screening were recruited. Patients with current or recent use of any biologic or current use of systemic steroids at a dose of more than 10 mg/day (prednisone) were excluded. Eligible patients were individually randomised (1:1) to parallel groups and received six injections over 12 weeks: subcutaneous dupilumab (600 mg once followed by 300 mg every 2 weeks) or subcutaneous placebo. Randomisation was performed using a central variable block (block sizes permuted between 2 and 4), with stratification by age (12-17 years or ≥18 years) and use (yes or no) of either systemic corticosteroids, swallowed corticosteroids for eosinophilic gastritis, or non-steroidal systemic immunosuppression therapy. Throughout the duration of the study, patients were expected to maintain their treatments or diets for eosinophilic gastritis. All patients who completed the double-blind period could enter the open-label extension at week 12, during which both groups received dupilumab until week 34. The primary endpoint of relative change from baseline in mean gastric eosinophil count from the five most eosinophil-dense HPFs in the gastric antrum and/or body was analysed at week 12 using linear regression. Secondary endpoints included absolute changes from baseline in Eosinophilic Gastritis Histologic Scoring System (EoS-HSS) total score, mean gastric eosinophil count from the five most eosinophil-dense HPFs, and Eosinophilic Gastritis Endoscopic Reference System (EoG-REFS) total score. All randomly assigned patients who received at least one dose of study drug were included in the safety analysis and efficacy analyses were done in all randomly assigned patients who received at least one dose of study drug and had outcome data available at week 12 (complete case). This study is registered with ClinicalTrials.gov (NCT03678545) and is now complete. FINDINGS: Between May 14, 2021, and Nov 10, 2023, we randomly assigned 41 patients, of whom 21 (51%) received dupilumab and 20 (49%) received placebo during the double-blind period and were included in the safety analysis. Patients were aged 12-59 years (mean 30·5 years [SD 13·2]; seven [17%] aged <18 years), 37 (90%) were White, one (2%) was Asian, one (2%) was Black or African American, two (5%) were of multiple races, 25 (61%) were female, and 16 (39%) were male. One patient from the placebo group withdrew before week 12; the remaining 21 patients treated with dupilumab and 19 patients treated with placebo had available data and were assessed for the primary endpoint. At week 12, the relative reduction in the primary endpoint was greater with dupilumab (estimated mean change -50% [95% CI -66 to -34]) than with placebo (-4% [-20 to 13]; difference -47 percentage points [-70 to -24]; p<0·0001). Significant differences between groups were noted for the secondary endpoints of absolute change from baseline in EoS-HSS total score (difference -0·10 [95% CI -0·18 to -0·03]; p=0·0055), absolute change from baseline in mean gastric eosinophil count (-38·8 [-75·6 to -17·8]; p=0·0008), and absolute change from baseline in EoG-REFS total score (-3·42 [-6·18 to -0·65]; p=0·016). At week 12, the incidence of treatment-emergent adverse events was similar between dupilumab (17 [81%]) and placebo (17 [85%]). The most common adverse event was blood eosinophilia, with similar incidence in the dupilumab (six [29%]) and placebo (six [30%]) groups. No serious adverse events or treatment-related deaths were reported. INTERPRETATION: The improvement of histological outcomes of eosinophilic gastritis with dupilumab in this proof-of-concept study shows type 2 inflammatory involvement in the disease and the potential value of dupilumab for the treatment of eosinophilic gastritis. FUNDING: National Institutes of Health, USA; Regeneron Pharmaceuticals Inc; and Sanofi.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhaoxi完成签到 ,获得积分10
1秒前
1秒前
丘比特的应助被zyf采纳,获得10
2秒前
jojo完成签到,获得积分10
2秒前
2秒前
kata完成签到,获得积分10
2秒前
南风完成签到,获得积分10
3秒前
夜寻发布了新的文献求助30
4秒前
无花果的应助被meng采纳,获得10
4秒前
zhikaiyici发布了新的文献求助30
5秒前
刘昊然的老婆完成签到 ,获得积分10
6秒前
liu发布了新的文献求助10
6秒前
Zhao完成签到 ,获得积分10
6秒前
Felix发布了新的文献求助10
7秒前
小蘑菇的应助被xiaoxiao采纳,获得10
8秒前
bad boy发布了新的文献求助10
8秒前
天天快乐的应助被李李李采纳,获得10
8秒前
9秒前
9秒前
小小鱼完成签到,获得积分10
9秒前
英俊的铭的应助被猪大肠采纳,获得10
10秒前
11秒前
11秒前
酷波er的应助被玩家666采纳,获得10
11秒前
11秒前
SciGPT的应助被夜寻采纳,获得30
12秒前
星辰大海的应助被魏同心采纳,获得10
12秒前
打打的应助被arcidia采纳,获得10
13秒前
14秒前
15秒前
MMLi发布了新的文献求助10
15秒前
zyf发布了新的文献求助10
15秒前
FashionBoy的应助被Jasmine采纳,获得10
15秒前
15秒前
16秒前
16秒前
毛毛发布了新的文献求助10
16秒前
maguodrgon发布了新的文献求助10
16秒前
深情可乐完成签到,获得积分10
16秒前
孙兆楠发布了新的文献求助200
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193653
求助须知:如何正确求助?哪些是违规求助? 9579816
关于积分的说明 21867585
捐赠科研通 7793288
什么是DOI,文献DOI怎么找? 3437343
关于科研通互助平台的介绍 2560779
邀请新用户注册赠送积分活动 2484193